Canapp et al., The effect of topical tripeptide-copper complex on healing of ischemic open wounds, Vet
What are the legal risks of DIY GLP-1 injections
Suggested table of clinical case studies (to include in article): columns for patient phenotype (age, BMI, diagnosis), peptide used (dose, duration), metabolic outcomes (weight change, HOMA-IR), reproductive outcomes (ovulation, oocyte yield, pregnancy), adverse events, and follow-up duration, such as PCOS, obesity-associated anovulation, poor ovarian response, and metabolic syndrome
Post-Therapy Monitoring & Wellness Coaching
Of note, in the SURPASS-4 trial, adjudicated major adverse cardiovascular events (MACE) were not increased with tirzepatide compared with insulin glargine over an extended follow-up period of 52 additional weeks after the main trial period of 52 weeks [21]